TP53 and metastatic neoplasm: Our results, strictly based on analyses of chemotherapy-naïve tumour samples from patients with synchronous metastatic disease, also demonstrate an inter-patient heterogeneity regarding known driver mutations, which is in line with previously published data on CRC, with TP53, APC, and KRAS being the most frequently mutated genes57,61.